Background
==========

In patients with acute coronary syndrome (ACS) who undergo percutaneous coronary interventions (PCI), common recommendations for antithrombotic regimens include dual antiplatelet therapy with aspirin and clopidogrel \[[@B1],[@B2]\]. Clopidogrel is a thienopyridine derivative metabolized by cytochrome P450 to an active metabolite that irreversibly inhibits platelet P2Y~12~ receptors \[[@B3]\]. Although the efficacy of clopidogrel has been well established, it exhibits pharmacodynamic variability in diverse conditions which can be due to the loss-of-function *CYP2C19* allele, drug-drug interactions or clinical factors \[[@B4]\]. High on-treatment platelet reactivity (HPR) after clopidogrel administration is associated with adverse cardiovascular events \[[@B5]-[@B11]\] and the rate of HPR can be reduced with either a higher loading dose (LD) or maintenance doses (MD) of clopidogrel, or a potent alternative drug \[[@B2],[@B12]-[@B14]\]. The use of double doses of clopidogrel and the more potent thienopyridine prasugrel to reduce HPR and subsequent cardiovascular events have not been successful, partially due to the studies being conducted with low event rates and low-risk patients \[[@B15],[@B16]\]. Another issue concerning prior study design has been the delayed administration of drugs, administered after PCI in both cases. Therefore, a platelet reactivity (PR) guided trial with reloading of a more potent drug in the early phase of ACS, especially before PCI, is warranted.

Prasugrel is also a thienopyridine derivative. However, the metabolism of prasugrel is much more efficient than that of clopidogrel, because it occurs via esterases and has less dependency on cytochrome P450 enzymes \[[@B17]\]. As a result, prasugrel treatment results in more rapid onset, more consistent conversion from the inactive prodrug to active metabolite, and higher blood concentrations of the active metabolite \[[@B18]\]. A LD of prasugrel 60 mg results in more rapid, potent and consistent inhibition of platelet function than clopidogrel LDs of 300 mg or 600 mg \[[@B19]\].

We hypothesize that for patients with HPR after an initial LD of clopidogrel, reloading with prasugrel in the early phase of ACS will reduce PR more effectively than reloading with clopidogrel, resulting in a reduction of adverse cardiovascular events.

Methods and design
==================

Trial objectives
----------------

The primary aim of this study is to compare PR if 20 mg of prasugrel is reloaded, followed by MDs of 5 mg daily, versus clopidogrel reloading with 300 mg followed by MDs of 75mg per day, prior to PCI in ACS patients with HPR after an initial LD of clopidogrel.

Study design
------------

PRAISE-HPR is a prospective, randomized, open-label, active controlled study with two parallel study groups. It will be conducted at Dong-A University Hospital in Busan, Republic of Korea. Participants will be randomly allocated into prasugrel or clopidogrel reloading groups. Clinical endpoints will be measured at four weeks post-procedure. Recruitment of participants began in November 2012. The overall study design is depicted in Figure [1](#F1){ref-type="fig"}. Study approval was granted by the Institutional Review Board (IRB) of Dong-A University Hospital, and consecutive, eligible patients will be required to provide written informed consent.

![**Overall study design.**ACS, acute coronary syndrome; UA, unstable angina; NSTEMI, myocardial infarction without ST-segment elevation; PCI, percutaneous coronary intervention; PR, platelet reactivity; MI, myocardial infarction.](1745-6215-14-62-1){#F1}

Randomization
-------------

Random treatment assignments will be generated using Excel spreadsheet software (Microsoft Corporation, Redmont, DC, USA). Eligible patients will be randomly assigned, on a 1:1 ratio, to receive reloading with either prasugrel or clopidogrel. Treatment randomization will be performed by independent personnel not involved in the study.

Approval
--------

This study will be conducted according to principles outlined in the Declaration of Helsinki. All patients must provide written informed consent, understanding that participation is voluntary and can be withdrawn at any time without any negative consequences concerning their current or future medical treatment. This study protocol has been approved by the IRB of Dong-A University Hospital.

Patient population
------------------

Male and female patients, aged between 20 and 80 years for which the decision to undergo PCI within 24 hours has been made, due to ACS without ST-segment elevation are eligible for the study (Table [1](#T1){ref-type="table"}).

###### 

Eligibility criteria

  **Inclusion criteria**                           **Exclusion criteria**
  ------------------------------------------------ ----------------------------------------------------------------------
  Subjects 20 to 80 years old                      Body weight \< 50 kg
  Male or female gender                            Contraindications for study drugs
  ACS without ST-segment elevation                 Urgent PCI for ACS
  Planned to undergo PCI                           Use of glycoprotein IIb/IIIa inhibitor
  Patients who provided written informed consent   History of transient ischemic attack
                                                   Active internal bleeding or bleeding diathesis
                                                   Upper gastrointestinal bleeding in the past six months
                                                   Hemoglobin \< 10 g/dl or platelets \< 100,000/mm^3^
                                                   Renal dysfunction (serum creatinine \> 2.5 mg/dl)
                                                   Hepatic dysfunction (serum transaminase \> three times normal limit)

ACS, acute coronary syndrome; PCI, percutaneous coronary intervention.

Patients requiring urgent PCI for ACS will be excluded from entry, as will those with recent or planned medical treatment with glycoprotein IIb/IIIa inhibitors, body weight \< 50 kg, contraindication to the study drug, a history of transient ischemic attack, active internal or bleeding diathesis, hemoglobin \< 10 g/dl, platelet count \< 100,000/mm^3^, renal insufficiency with serum creatinine level \> 2.5 mg/dl or significant hepatic dysfunction.

Intervention and comparator descriptions
----------------------------------------

Before randomization, 300 mg of aspirin and 600 mg of clopidogrel will be administered as LDs according to the conventional guidelines for ACS \[[@B2]\]. For those who have already been receiving clopidogrel for five days or more, 300 mg of clopidogrel will be administered as a LD. PR will be evaluated before PCI and defined as the time between the arrival of the patient at the angiography room, and the beginning of coronary angiography. Angiography will not begin before confirmation of PRU. Patients who exhibit HPR defined as a PRU value of 240 units or more by VerifyNow (Accumetrics, San Diego, CA, USA) will be randomized and followed by assignment to either the clopidogrel reloading group (clopidogrel 300 mg) or the prasugrel reloading group (prasugrel 20 mg). Angiography in patients with HPR will begin after administration of the study drug. PR will be checked serially using the VerifyNow (Accumetrics, San Diego, CA, USA) assay at four hours, 24 hours and 30 days after PCI. Patients will be required to visit the outpatient clinic at Day 30 for measurement of PR. For patients discharged before Day 8, a secondary visit at Day 15 will be recommended.

In the clopidogrel reloading group, 300 mg clopidogrel will be reloaded, followed by MDs of clopidogrel 75 mg/day for 30 days. In the prasugrel reloading group, 20 mg of prasugrel will be reloaded, followed by prasugrel administration of 5 mg/day for 30 days.

Measurement of outcomes
-----------------------

The primary endpoint of this study will be HPR at 24 hours after PCI, as determined by the VerifyNow (Accumetrics, San Diego, CA, USA) assay during the study period (Table [2](#T2){ref-type="table"}). The optimal cutoff value is defined as 240 units, as observed by Marcucci *et al*. \[[@B9]\]. Secondary endpoints include major adverse cardiovascular events at 30 days after PCI, including death from cardiovascular cause, myocardial infarction (MI), stent thrombosis, hemorrhagic or non-hemorrhagic stroke, and bleeding events defined by Thrombolysis in Myocardial Infarction (TIMI), as well as Bleeding Academic Research Consortium (BARC) criteria. HPR at four hours or 30 days after PCI will also be evaluated.

###### 

Primary and secondary outcomes

  **Primary outcome**    **Secondary outcomes**
  ---------------------- ------------------------------------------------------------------------------------------
  HPR (PR ≥ 240 units)   Death from cardiovascular cause
                         Myocardial infarction
                         Stent thrombosis
                         Hemorrhagic or non-hemorrhagic stroke
                         Target vessel revascularization
                         Bleeding event defined by Thrombolysis in Myocardial Infarction (TIMI) criteria and BARC

HPR, high platelet reactivity: more than 240 units determined via VerifyNow (Accumetrics, San Diego, CA, USA); PR, platelet reactivity; BARC, bleeding academic research consortium.

Adverse effects
---------------

Patients will be interviewed daily during admission and at each visit after discharge regarding the occurrence of any adverse events, including time of onset, duration and severity. At each interview, patients will be assessed for reported bleeding classified by the TIMI bleeding classification scheme \[[@B20]\] as well as the BARC definition \[[@B21]\]. All information regarding adverse events will be to be presented on a case report form. The causal relation to the study drug and the intensity of adverse events will be evaluated by the investigators. Serious adverse events will be reported to the IRB and study sponsor by the principal investigator within 24 hours of being reported by the subjects or the treating physicians.

Withdrawals
-----------

Participants are free to withdraw from trial participation at their own request at any time without giving reasons for their decisions. Additionally, the primary investigator may withdraw study participants if continuation of the trial is deemed to be detrimental to the patient's well-being. Withdrawals will be documented in the case report form and in the patient's medical records with active follow-up for ongoing severe adverse events. Distinction will be made between patients who 'withdraw from the study' versus 'withdraw from the treatment' in order to preserve the ability to analyze endpoints for all participants who underwent randomization, allowing for the later possibility of intention-to-treat inferences.

Sample size
-----------

The sample size calculation is based on the primary outcome and the primary analysis for the intention-to-treat population. The sample size is calculated using the study's primary objective to detect a 15% difference in PR suppression between reloading with prasugrel and clopidogrel, to a power of 80% to demonstrate difference. On the basis of previous reports we assume the inhibition of PR after a LD of clopidogrel to be approximately 55% of baseline \[[@B22]\]. The assumed inhibition of PR after LD of prasugrel is 70%. This was calculated from studies showing a 30% higher concentration of the active metabolite in patients of East Asian ethnicity \[[@B23]\] and an approximate 90% inhibition of baseline PRU two hours after a prasugrel 30 mg LD was given in healthy Korean people \[[@B24]\]. We expect the difference in PR inhibition will be at least 15% when considering ACS patients. We adjusted the sample size for an estimated follow-up loss rate of 20%, a two-sided level of significance of α = 5%, which determined that 38 patients in each group would be required to detect this difference with a two-sided Student's *t* test. A total of 76 patients will be randomized and included in the analysis. We predict that 50% of patients will exhibit HPR as determined by VerifyNow (Accumetrics, San Diego, CA, USA) after receiving the clopidogrel LD. A total of 152 patients will be screened and 76 patients will be randomized and included in the analysis, with 38 patients in each group.

Statistical analysis
--------------------

The focus of this trial is to compare the efficacy and safety between both study groups. The statistical analyses will be performed on the full analysis set, which will include data from all randomized patients receiving at least one dose of study medication. The safety analysis will include calculation of frequencies, rates of complications, and occurrence of any serious adverse events reported in the two groups.

Descriptive statistics will be calculated according to the scale level of the variables. Continuous data will be analyzed using Student's *t* test. The chi-square test will be used for categorical variables. A value of *P* \< 0.05 will be used to denote statistical significance.

The effect of treatment will be expressed as relative risk estimates and absolute risk reduction. The primary outcome will be analyzed using multivariate logistic regression, adjusting for clinically relevant baseline imbalances. The remaining secondary outcomes will be analyzed using simple 2 × 2 tables and logistic regression. In all analyses, statistical uncertainty will be quantified via 95% confidence intervals. All statistical data will be analyzed using SPSS Version 12.0 (SPCC Inc., Chicago, IL, USA).

Discussion
==========

Although clopidogrel is an effective antiplatelet agent, variability in patient response and potential high PR remains a major shortfall. To date, recent studies focusing on tailored antiplatelet therapy have not shown benefits. However, a study comparing the efficacy of prasugrel and clopidogrel in early reloading for the management of HPR after clopidogrel LD has not been conducted. In addition, guidelines for managing HPR before or during PCI in ACS patients have not documented.

Our current investigation into reloading prasugrel versus clopidogrel for reductions of HPR in ACS patients undergoing PCI is based on the hypothesis that prasugrel reloading is superior to clopidogrel for HPR and adverse event reduction, including periprocedural MI. Our protocol design has some safeguards to avoid performance and evaluation bias. Randomization will be performed with computer software. Data will be recorded and analyzed by specialists who are not aware of treatment allocation.

A major safety concern for this trial is an increased risk of bleeding. In TRITON-TIMI 38, higher rates of bleeding (particularly non-coronary artery bypass graft-related TIMI major bleeding) were observed in the prasugrel group \[[@B25]\]. However, in comparison to clopidogrel, prasugrel provided greater protection from ischemic events (particularly stent thrombosis, urgent revascularization and MI). We therefore anticipate that the benefit of antiplatelet efficacy will outweigh the increased risk of bleeding.

Regarding the issue of loading and maintenance doses, previous reports have revealed that patients of East Asian ethnicity exhibit on average 30% higher levels of active metabolite compared to Caucasians, with the implication that exposure of mean doses of prasugrel to Asian subjects may not be appropriate \[[@B23]\]. Other studies focused on Chinese subjects have determined that 30 mg of prasugrel produces higher concentrations of active metabolite and greater platelet inhibition than 300 mg of clopidogrel \[[@B26]\]. Peak levels of prasugrel active metabolites were found to be 67% higher in Chinese subjects (calculated to be 39% higher after adjustment for differences in body weight) than in Caucasian volunteers. Taking into account ethnic differences in body weight and body mass index, subjects of North-East Asian ethnicity appear to receive comparable effects with lower prasugrel LDs and MDs. In an additional study conducted by our team, healthy Korean volunteers administered with a 30 mg LD of prasugrel exhibited significantly greater and more rapid inhibition of PR than those administered with a clopidogrel LD of 600 mg \[[@B24]\]. Yokoi *et al*. compared several different prasugrel LDs and MDs in Japanese patients and reported similar effects for a 10 mg LD/ 2.5mg MD prasugrel regimen to a 300mg LD/75 mg MD clopidogrel regimen \[[@B27]\]. These dosages are one sixth and one fourth, respectively, of the current LD and MD recommended by the manufacturer. We plan to conduct the present study with lower LDs and MDs of prasugrel than doses previously recommended.

Due to its rapid onset of action, the use of prasugrel can be particularly favorable in patients requiring PCI at the time of angiography who have not received thienopyridine loading. LDs of prasugrel can be expected to provide more potent platelet inhibition within a short period of time for PCI support. The use of prasugrel therefore appears particularly suitable for patients undergoing PCI within hours of the decision to use a thienopyridine. Furthermore, this rapid onset agent can be administered immediately prior to, or during PCI. This is particularly relevant for patients with HPR remaining after a LD of clopidogrel.

The GRAVITAS \[[@B16]\] and TRIGGER-PCI \[[@B15]\] trials aimed to detect reductions in HPR and concluded negative results. However, these studies did not use reloading or include high risk, acute phase patients. Our study is therefore the first to involve early manipulation of HPR using a more potent agent before or during PCI. The TRITON-TIMI 38 trial was noted for a lack of clopidogrel loading before randomization. Our trial design addresses some ethical issues arising from such protocols, due to closer similarities with real-world treatment. We anticipate that our study will reveal the possible role of prasugrel reloading and maintenance in improving clinical outcomes, emphasizing its potential to become an integral component in the management of patients undergoing PCI with remaining HPR after a loading dose of clopidogrel.

Trial status
============

PRAISE-HPR began randomizing patients in November 2012. The principle investigator can be contacted by Email.
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